Men with coronary artery disease who used phosphodiesterase-5 (PDE-5) inhibitors for erectile dysfunction had fewer adverse cardiovascular events than those taking the prostaglandin drug alprostadil ...

Men with stable CAD who are being treated for erectile dysfunction (ED) have a lower risk of dying if their medication is a phosphodiesterase 5 (PDE5) inhibitor rather than alprostadil, observational ...

Please provide your email address to receive an email when new articles are posted on . In a comparison of two erectile dysfunction medications in men with stable CAD, phosphodiesterase type 5, or ...

DRAMATIC ADVANCES IN THE MANAGEMENT of erectile dysfunction have occurred over the past decade. Oral therapy with vasoactive agents has emerged as first-line treatment and has transformed both the ...

SAN DIEGO, March 31, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that the Mexican Patent Office ("MPO") will grant an additional patent for ...

Asafu-Adjei is a board-certified urologist and is fellowship-trained in male sexual dysfunction and infertility. As a board-certified urologist who specializes in male sexual dysfunction and men’s ...

Erectile dysfunction (ED) is more common than many men realize and is often linked to a mix of physical, emotional, and lifestyle factors. Urologist John Smith, MD, explains what causes ED, how ...